DBH deficiency in an elderly patient: efficacy and safety of chronic droxidopa

Fabien Despas; A Pathak; M Berry; R Cagnac; P Massabuau; E Liozon; M Galinier; J M Senard

doi:10.1007/s10286-009-0049-7

DBH deficiency in an elderly patient: efficacy and safety of chronic droxidopa

Clin Auton Res. 2010 Jun;20(3):205-7. doi: 10.1007/s10286-009-0049-7. Epub 2010 Jan 9.

Authors

Fabien Despas¹, A Pathak, M Berry, R Cagnac, P Massabuau, E Liozon, M Galinier, J M Senard

Affiliation

¹ INSERM U858 équipe 8, 31432 Toulouse, France. [email protected]

PMID: 20063034
DOI: 10.1007/s10286-009-0049-7

Abstract

We describe the effects of chronic droxidopa in a patient with Dopamine beta-hydroxylase deficiency diagnosed at the age of 73. Investigations were performed to assess sympathetic activity (MIBG scintigraphy, catecholamines) and cardiovascular droxidopa safety.

Publication types

Case Reports

MeSH terms

3-Iodobenzylguanidine
Aged
Autonomic Nervous System Diseases / diagnosis
Autonomic Nervous System Diseases / diagnostic imaging
Autonomic Nervous System Diseases / drug therapy*
Autonomic Nervous System Diseases / enzymology*
Catecholamines / blood
Dopamine beta-Hydroxylase / deficiency*
Droxidopa / therapeutic use*
Humans
Hypotension, Orthostatic / complications
Male
Radionuclide Imaging
Radiopharmaceuticals

Substances

Catecholamines
Radiopharmaceuticals
3-Iodobenzylguanidine
Dopamine beta-Hydroxylase
Droxidopa